Potassium canrenoate
| Clinical data | |
|---|---|
| Other names | SC-14266 |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Intravenous |
| ATC code | |
| Pharmacokinetic data | |
| Metabolism | Hepatic |
| Excretion | Renal and fecal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| E number | {{#property:P628}} |
| CompTox Dashboard (EPA) |
|
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C22H29KO4 |
| Molar mass | 396.568 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Potassium canrenoate (INN, JAN) or canrenoate potassium (USAN) (brand names Venactone, Soldactone), also known as aldadiene kalium,[1] the potassium salt of canrenoic acid, is an aldosterone antagonist of the spirolactone group.[2] Like spironolactone, it is a prodrug, and is metabolized to active canrenone in the body.[3][4]
Potassium canrenoate is notable in that it is the only clinically used antimineralocorticoid which is available for parenteral administration (specifically intravenous)[4][5] as opposed to oral administration.[6]
In the UK, it is unlicensed and only used for short term diuresis in oedema or heart failure in neonates or children under specialist initiation and monitoring.
See also
[edit | edit source]References
[edit | edit source]- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ a b Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
| Sulfonamides (and etacrynic acid) |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Potassium-sparing (at CD) |
| ||||||||
| Osmotic diuretics (PT, DL) | |||||||||
| Vasopressin receptor inhibitors (DCT and CD) | |||||||||
| Other | |||||||||
| Combination products | |||||||||
| |||||||||
| Mineralocorticoids | |
|---|---|
| Antimineralocorticoids | |
| Synthesis modifiers | |
| |
| MRTooltip Mineralocorticoid receptor |
| ||||
|---|---|---|---|---|---|
| PRTooltip Progesterone receptor |
| ||||||
|---|---|---|---|---|---|---|---|
| mPRTooltip Membrane progesterone receptor (PAQRTooltip Progestin and adipoQ receptor) |
| ||||||
| ARTooltip Androgen receptor |
| ||||||
|---|---|---|---|---|---|---|---|
| GPRC6A |
| ||||||
This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
- Pages with script errors
- Articles with short description
- Articles with changed CASNo identifier
- Articles with changed DrugBank identifier
- Articles with changed EBI identifier
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without KEGG source
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- All stub articles